A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

A small percentage have had vision problems, but a direct causal link with the drugs has not been established.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

Winfrey opened up about her decision to use a medication to help her lose weight in an interview with People. Her new TV ...